Trial Profile
Maraviroc Plus Darunavir/Ritonavir Study for Treatment-Naive Patients Infected With R5-tropic HIV-1 Based on Enhanced Sensitivity Trofile.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Darunavir (Primary) ; Maraviroc (Primary) ; Ritonavir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms MIDAS
- 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Jul 2012 Planned End Date changed from 1 Jan 2013 to 1 Feb 2013 as reported by ClinicalTrials.gov.
- 13 Jun 2011 Planned end date changed from 1 Dec 2011 to 1 Jan 2013 as reported by ClinicalTrials.gov.